Our Story
PharmaBlock (Stock code: 300725.SZSE) is a leading provider of innovative chemistry products and services throughout the pharmaceutical R&D process and commercial manufacturing. Its dedication to advancing innovation in chemistry and low-carbon manufacturing supports partners to accelerate drug R&D, ensure consistent quality, reduce R&D and manufacturing cost, and foster a greener and more sustainable future.
Officially operated in 2008, PharmaBlock has partnered with almost all the top 20 pharmaceutical companies and hundreds of biotech companies around the world. Its core businesses began with building blocks for drug discovery, and after establishing experience developing robust and scalable processes for manufacturing thousands of compounds, PharmaBlock grew into a research, development & GMP manufacturing service partner for global pharmaceutical and biotech companies.
The company has also developed a comprehensive suite of solutions, featuring flow chemistry, micropacked bed hydrogenation, biocatalysis, heterogeneous catalysis, etc., to reduce the carbon footprint, address the chemical challenges, and make pharmaceutical production more efficient and safer.
Novel Building Blocks
Since its establishment, PharmaBlock has rapidly gained recognition for its proficiency in the design, synthesis, and supply of novel building blocks. The team has generated a large and unique collection of high-quality and diverse building blocks, that cater to the majority of R&D needs for small molecule drugs and new modalities like peptide, oligonucleotide, ADC and TPD drugs.
These building blocks are increasingly adopted by drug hunters to enrich the structure options, improve compound quality, expand patent space and eventually accelerate drug discovery projects. PharmaBlock has also established robust and scalable processes for manufacturing thousands of building blocks, securing the sustainable supply of these compounds.
Leveraging its unique advantages of quick access to in-house building blocks and chemistry expertise, PharmaBlock has extended its business scope from a building block supplier to a more comprehensive CRDMO services and solutions provider to pharmaceutical and biotech partners.
Chemistry Research Service
With strong chemistry expertise and quick access to the large and unique collection of building blocks, PharmaBlock has established a high-efficient platform, delivering synthetic and medicinal chemistry services to global pharmaceutical and biotech customers. These services aid in the discovery of preclinical candidates through hit-to-lead and lead optimization solutions. This platform also includes a set of efficient tools, including but not limited to Fragment-based Library for Drug Design (FBDD), DNA-encoded Library Technology (DELT), and Virtual Screening.
CDMO Service
PharmaBlock offers development and manufacturing solutions for pharmaceutical intermediates, RSMs, drug substances, and drug products at all stages, from development to commercialization. Leveraging its wealth of building blocks and expertise in chemistry, process R&D, analytical development, GMP manufacturing, low-carbon technologies, and regulatory affairs, the team excels in delivering integrated CMC (Chemistry, Manufacturing, and Control) solutions. It solves challenging chemistry problems, ensures reliable supply, controls costs, and fully complies with quality and EHS standards. PharmaBlock continues to evolve, adding new capabilities and developing a comprehensive suite of solutions to serve customers across the drug development spectrum.
Technology Innovation
At PharmaBlock, technology innovation is an essential component of our commitment to providing efficient, high-quality, and reliable services to partners, and fulfilling our social responsibility. The company has developed a comprehensive suite of solutions, featuring flow chemistry, micropacked bed hydrogenation, biocatalysis, heterogeneous catalysis, etc., to reduce the carbon footprint, address the chemical challenges, and make pharmaceutical production more efficient and safer.
The development and application of new technologies has enabled more innovative solutions, with shortened lead time and reduced overall costs for development and manufacturing projects, and bring long-term value to our customers.
To recognize PharmaBlock's outstanding efforts and achievement in green chemistry in support of pharmaceutical research, development, and manufacturing, American Chemical Society (ACS) Green Chemistry Institute Pharmaceutical Roundtable (GCI PR) presented PharmaBlock 2023, 2024 CMO Excellence in Green Chemistry Award, for two consecutive years.
